Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ: CRSP )

40.94 +0.46 (+1.14%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 759,869
Open 40.48
Bid (Size) 40.82 (1)
Ask (Size) 40.94 (1)
Prev. Close 40.48
Today's Range 39.80 - 41.02
52wk Range 39.41 - 91.10
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
Via The Motley Fool
1 big new Green Flag for CRISPR Therapeutics' Stock
Via The Motley Fool

Performance

YTD
-38.03%
-38.03%
1 Month
-18.77%
-18.77%
3 Month
-12.50%
-12.50%
6 Month
-26.83%
-26.83%
1 Year
-37.33%
-37.33%

More News

Read More
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
Via Investor's Business Daily
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Via The Motley Fool
3 Things You Need to Know if You Buy CRISPR Therapeutics Today
Via The Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in December
Via The Motley Fool
Where Will CRISPR Therapeutics Be in 3 Years?
Via The Motley Fool
3 of the Best Growth Stocks You Can Buy for Less than $100
Via The Motley Fool
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%
Via The Motley Fool
Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
Via Benzinga
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
3 Monster Stocks in the Making
Via The Motley Fool
Deciphering Disruption: Inside Cathie Wood's Latest Plays
Via MarketBeat
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
Via The Motley Fool
3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
Smaller Cap Biotechs Are In Season: How Are We Doing?
Via Talk Markets
3 Companies Building Tomorrow's Game-Changing Technologies
Via The Motley Fool
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
Via The Motley Fool
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
12 High-Growth Stocks That Could Deliver Parabolic Returns
Via The Motley Fool
The Ultimate Biotech Stock to Buy With $50 Right Now
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.